



FEATURES OF THE COURSE OF PREGNANCY IN PATIENTS WITH CONNECTIVE TISSUE DYSPLASIA

Khudoyarova Dildora Rakhimovna

Professor

Shodikulova Gulandon Zikiriyayevna

Professor

Yunusova Zarnigor Maksadovna

Assistant

<https://doi.org/10.5281/zenodo.13999705>

ARTICLE INFO

Received: 21th October 2024

Accepted: 27th October 2024

Online: 28th October 2024

KEYWORDS

Connective tissue dysplasia, hemostasis, complications of pregnancy and childbirth, magnesium deficiency, endothelial dysfunction, markers of collagen breakdown, genital prolapse.

ABSTRACT

The article is devoted to the problems associated with connective tissue dysplasia (CTD), predominantly undifferentiated forms of the disease (nDST). The topic's relevance is due to the high prevalence of this pathological condition. The generalized nature of connective tissue damage with the involvement of the reproductive system in the pathological process significantly affects the course of pregnancy and Birth. Complications that may be associated with pregnancy, childbirth, and the postpartum period in women with nDST and which cause a high need for surgical aids: amnio-, episio- and perineotomy, and cesarean section are presented. Particular attention is paid to magnesium, which plays one of the determining roles in the complex biosynthesis of the extracellular matrix in the formation of connective tissue and the morphofunctional state of fibroblasts. The methods used to detect connective tissue metabolism disorders (determination of the level of oxyproline and fibronectin in blood serum, pyrinx D and glucosaminoglycans in urine, etc.) are described. Given the lack of reliable diagnostic (biochemical and genetic) criteria for nDST, special attention is paid to the need for an integrated approach to assessing the condition of patients using anamnesis data, and the results of clinical, instrumental, and laboratory examinations.

BIRIKTIRUVCHI TO'QIMA DISPLAZIYASI BO'LGAN BEMORLARDA HOMILADORLIK KECHISHINING XUSUSIYATLARI

Xudoyarova Dildora Rahimovna

Professor

Shodiqulova Gulandon Zikiriyayevna

Professor

Yunusova Zarnigor Maksadovna

Assistant



ARTICLE INFO

Received: 21th October 2024

Accepted: 27th October 2024

Online: 28th October 2024

KEYWORDS

Biriktiruvchi to'qima displaziyasi, gemostaz, homiladorlik va tug'ruq asoratlari, magniy yetishmovchiligi, endotelial disfunktsiya, kollagen parchalanishining markerlari, genital prolaps.

ABSTRACT

Maqola biriktiruvchi to'qima displazi (BTD), asosan kasallikning differensiallanmagan shakllari (nDST) bilan bog'liq muammolarga bag'ishlangan. Mavzuning dolzarbligi ushbu patologik holatning keng tarqalishi bilan bog'liq. Reproduktiv tizimning patologik jarayonda ishtirok etishi bilan biriktiruvchi to'qimalarning shikastlanishining umumiy tabiati homiladorlik va tug'ruq jarayoniga sezilarli darajada ta'sir qiladi. nDST bilan xastalangan ayollarda homiladorlik, tug'ruq va tug'ruqdan keyingi davr bilan bog'liq bo'lishi mumkin bo'lgan va jarrohlik yordamiga katta ehtiyojni keltirib chiqaradigan asoratlari: amnio-, epizio- va perineotomiya va kesarcha kesish. Biriktiruvchi to'qima va fibroblastlarning morfofunktsional holatini shakllantirishda hujayradan tashqari matritsaning murakkab biosintezida hal qiluvchi rollardan birini o'ynaydigan magniyga alohida e'tibor beriladi. Biriktiruvchi to'qima almashinuvi buzilishlarini aniqlashda qo'llaniladigan usullar (qon zardobida oksiprolin va fibronektin, siydikda D pirinks va glyukozaminoglikanlar darajasini aniqlash va boshqalar) tavsiflanadi. nDST uchun ishonchli diagnostik (biokimyoviy va genetik) mezonlarning yo'qligini hisobga olgan holda, anamnez ma'lumotlari, klinik, instrumental va laboratoriya tekshiruvlari natijalaridan foydalangan holda bemorlarning ahvolini baholashga kompleks yondashuv zarurligiga alohida e'tibor qaratiladi.

Introduction. Considerable attention to connective tissue dysplasia (CTD) is associated with the wide prevalence of its manifestations in the population, which ranges from 26 to 80% [1, 2]. For example, the incidence of small undifferentiated forms is 68.8% [3, 4]. Various combinations of DST's external and internal manifestations cause various connective tissue syndromes and non-syndromic forms [5–7].

DST is a nutritionally and genetically determined condition that develops as a result of impaired connective tissue metabolism in the embryonic and postnatal periods and is characterized by abnormalities in the structure of the components of the extracellular matrix (fibers and the main substance of the gel-like medium) with progressive morphofunctional changes in various systems and organs [8–13].

Depending on the etiology, differentiated and undifferentiated forms of DST are distinguished. Differentiated (syndromic) forms of DST include diseases of a monofactorial nature with an established gene defect, a known type of inheritance, and with a pronounced and well-defined clinical picture. Classic examples of syndromic forms of DST are Marfan and



Ehlers-Danlos syndromes, osteogenesis imperfecta, and some other rare genetic syndromes [14–17].

Undifferentiated forms of DST (nDST) have a polygenic-multifactorial nature. That is, the causes of the development of this pathological process are polymorphisms or mutations of a large number of genes in various combinations, as well as the impact of various environmental factors. Clinical manifestations of dCST (scoliosis, severe flat feet, joint hypermobility, varicose veins, hemorrhoids, mitral valve prolapse, hernias, myopia, genital prolapse, etc.) do not fit into any of the known differentiated hereditary diseases, although sometimes the clinical picture may be similar [1, 5, 10, 18, 19]. However, despite the high prevalence of nDST in the population, its recognition rate does not exceed 2.4% [3, 5, 9].

Interestingly, the combination of individual features of dST is the basis for the diagnosis of DST, but a single feature may not be strictly specific to dysplasia [10, 20]. The generalized nature of connective tissue damage with the involvement of the reproductive system in the pathological process significantly affects the course of pregnancy and childbirth. However, this aspect of the problem of cSTT remains insufficiently studied [3, 9].

Control of collagen synthesis is carried out at all its stages and depends on specific enzymes (at different stages these are ascorbic acid, copper, calcium, iron, selenium, zinc, etc.) [1, 21]. It is known that magnesium plays one of the determining roles in the complex biosynthesis of the extracellular matrix in the formation of connective tissue and the morphofunctional state of fibroblasts [22, 23].

Magnesium is one of the main elements that participates in the provision of important biochemical and physiological processes in the human body, it takes part in energy, plastic and electrolyte metabolism, and stimulates many cellular processes [1, 22]. Physiologically, magnesium metabolism in the body is a prerequisite for human health [10, 24]. In 1994, the World Health Organization classified magnesium deficiency as a disease with its ICD-10 code: E 61.3. The diagnosis of magnesium deficiency is more common as a concomitant. In Russia, the prevalence of magnesium deficiency among the population ranges from 16 to 42% [25], i.e. it is one of the most common types of nutrient deficiency in the population, which, of course, cannot but affect the quality of pregnancy [26, 27].

For women of childbearing age, the need for magnesium, provided that its content is initially normal, is 280 mg/day, for women during pregnancy — 350 mg/day, during lactation — 390 mg/day [10]. A more precise daily requirement for magnesium for pregnant and lactating women is 10–15 mg per 1 kg of body weight and 5 mg per 1 kg of body weight for healthy adults [10].

Magnesium deficiency in pregnant women with DST exacerbates existing disorders of collagen synthesis and forms a vicious circle that worsens the course of pregnancy. In general, patients with DST, especially those with magnesium deficiency, have a significantly higher risk of complications during pregnancy and childbirth than in the general population [26, 27]. Deficiency of the above-mentioned vitamins and minerals can also cause pregnancy complications [2, 5].

Features of the course of pregnancy in patients with DST

DST is a condition associated with the risk of developing various obstetric complications [9, 28–30].



Connective tissue forms a supporting framework for all tissues and organs and has a shape-determining significance, so its condition has a significant impact on the course and outcome of pregnancy, among other things. It is known that preeclampsia is significantly more common in connective tissue pathology, which ranks 2nd–3rd in the structure of causes of maternal mortality and is the main cause of perinatal mortality and morbidity [3]. 12.5–21.9% of women with nDST have preterm birth [3, 31]. In this category of patients, abnormalities of labor are often observed, untimely outpouring of amniotic fluid, and primary weakness of contractions is more often developed [32, 33]. Premature rupture of amniotic fluid, in turn, significantly increases the risk of placental abruption and the development of infectious complications [26, 29, 33]. Bleeding in the postpartum and early postpartum periods occurs in 7–12.7% of parturient women with nDST [34], which may be caused by impaired contractile activity and changes in the vascular system. Changes in blood flow velocity and venous pressure in patients with nDST with visceral manifestations, especially in cardiovascular pathology, affect uteroplacental circulation and, ultimately, uterine contractile activity and fetal condition [35]. Also, in women with nDST, the incidence of birth injuries (perineal, vaginal, and cervical ruptures) reaches 21.7–26.8%, which is associated with a systemic defect of the connective tissue [3, 9]. In addition, patients with DST often have uterine scar failure. These complications during pregnancy, childbirth and the postpartum period are the reason for the high need for surgical aids: amnio-, episio- and perineotomy, cesarean section [36].

DST plays an important role in the development of isthmic-cervical insufficiency. Some authors argue that with a low Varge index, the presence of phenotypic markers of DST, and an increase in the level of oxyproline in daily urine, the development of isthmic-cervical insufficiency can be predicted with a high probability [37, 38].

The more pronounced the manifestations of DST at the multi-organ level, the more often rapid and rapid labor occurs. In this case, pathological childbirth is a provoking factor that triggers the mechanism of genital prolapse formation, which progresses rapidly, is more difficult to surgically correct, and is characterized by a high recurrence rate in the postoperative period [4, 5]. The severity of genital prolapse and the timing of its occurrence are directly related to the severity of the clinical manifestations of nDST [4].

In women with nDST, fetal and newborn pathology, intrauterine growth retardation, chronic fetal hypoxia are more often registered, premature babies are born three times more often, and the percentage of sick newborns is higher. Congenital malformations (cryptorchidism, hip dysplasia) are more common in the morbidity of newborns from mothers with nDST. Babies are born with a lower birth weight and a low Apgar score [9, 29].

Both pregnancy and nDST adversely affect collagen metabolism. Deficiency of a number of micronutrients in pregnant women with nDST contributes to its aggravation. Magnesium is one of the main cofactors of connective tissue metabolism enzymes. Magnesium deficiency is known to contribute to the development of placental insufficiency with a 12-fold increase in the incidence of fetal growth retardation (odds ratio 12.6; 95% confidence interval 1.5–106; $p=0.0015$) [36].

Physiological pregnancy is characterized by an increase in coagulant potential and an almost twofold increase in the content of all coagulation factors against the background of a



decrease in fibrinolytic and anticoagulant activity [39]. Trophoblast invasion and normal functioning of the placenta are complex processes of endothelial-hemostasiological interactions with complex regulation. Disturbance of trophoblast invasion processes against the background of endothelial dysfunction syndrome does not lead to physiological reorganization of spiral arteries, and they remain sensitive to pathological changes in the hemodynamics of the maternal body. The progression of pregnancy in such conditions leads to impaired placental perfusion and subsequent complications, such as miscarriage, preeclampsia, placental insufficiency, premature abruption of the normally located placenta, and fetal growth retardation [29, 34, 36]. Probably, it is endothelial dysfunction that develops in pregnant women suffering from diabetes mellitus, chronic arterial hypertension, autoimmune diseases, and thrombophilias, which leads to impaired microcirculation in the placenta and prevents the normal course of pregnancy [7].

Generalized decrease in collagen content in tissues in pregnant women is often associated with inferiority of the vascular-platelet link of hemostasis, weakening of the ability of platelets to aggregate and impaired release reaction, platelet adhesion, clot retraction [40], and impaired coagulation hemostasis, characterized by a quantitative decrease in blood coagulation factors (VIII, IX) [40–42].

Thrombohemorrhagic syndrome in pregnancy in patients with nDST is characterized by scattered intravascular coagulation of the blood with the formation of many microclots of fibrin and aggregates of blood cells that block microcirculation in vital organs. However, shifts in the hemostatic potential of blood in patients with nDST also occur due to an imbalance of macro- and microelements, and an insufficient content of essential metals [40]. There is evidence in the literature that micro- and macronutrient deficiencies in pregnant women with nDST contribute to the disruption of the hemocoagulation cascade and uteroplacental blood flow [43].

Diagnosis of DST

There are clinical criteria for assessing the severity of DST [4]. Each symptom is scored in points, the number of points is summed up, and the severity of DST is determined. The sum of points up to 9 corresponds to mild severity (mild), from 10 to 16 - moderate severity (moderate), from 17 and above - severe (pronounced).

In older patients, it can be difficult to differentiate between involutive changes and manifestations of DST, since dysplastic signs after the age of 25 often reflect a genetically programmed process of connective tissue degradation [44]. Specialists have calculated coefficients for many external and internal signs of DST, which determine their importance in making a diagnosis. For example, the diagnostic coefficient for spinal scoliosis from adolescence is 13.53, for myopia — 5.74, etc. If the sum of the points when adding up the diagnostic coefficients of symptoms reaches the minimum threshold of 17, then this indicates with a probability of 95% that the patient has DST [2].

As mentioned above, despite the high prevalence of nDST in the population and the developed special diagnostic criteria [1, 2, 4] based on clinical manifestations, the recognition of this pathological process does not exceed 2.4% [3, 5, 9].

Due to the imperfection of methods for diagnosing DST, there is an obvious need for a biochemical study of the metabolism of structural components of connective tissue. For this



purpose, metabolites of collagen breakdown are determined, which are actively used as laboratory markers of osteoporosis, indicating the degree of bone tissue resorption. Based on the results of the research, we can indirectly judge the degree of severity of DST. In addition, biochemical techniques can be used in the course of dynamic observation to assess the effectiveness of measures taken to prevent connective tissue complications and to predict the course of the dysplastic process [5].

Of the protein components of the fibrous part of the connective tissue, *oxyproline is most often studied* in serum according to the method of R.E. Neuman and M.A. Logan, and in urine according to the method of L. Bergman and R. Loxley. Biomaterial sampling is carried out after following a restrictive diet for the previous three days [1, 2, 5].

The ratio of total and free oxyproline in daily urine can be used to judge the degree of connective tissue metabolism disorders. However, for diagnostic purposes, it is important that the intensity of oxyproline release significantly depends on the patient's age, time of day, and diet [1, 4]. The amount of oxyproline in the urine depends on the intake of collagen with food, so some authors suggest that this method of study should be carried out after a 12-hour fast, which, in their opinion, excludes the influence of food collagen on the examination result [9, 45, 46].

There is also evidence of a high correlation between increased serum oxyproline levels and the results of immunohistochemical examination of tissues, indicating pelvic floor muscle failure. In the course of the study, it was revealed that the determination of the level of oxyproline has low specificity and is not informative in itself. To improve the quality of nDST diagnosis, it is necessary to compare laboratory markers with clinical data [45, 46].

The content of C-terminal (carboxyterminal) and N-terminal (aminoterminal) telopeptides (breakdown products of type I collagen) *in blood serum is also of certain importance*. These are the non-spiralized ends of procollagen that are cleaved during collagen maturation [1, 4]. There is an inverse relationship between the amount of these telopeptides and collagen synthesis in the cell, i.e., the more telopeptides outside the cell, the less collagen synthesis [4].

Determination of the level of pyrilink D (DPID, deoxypyridinoline) in the urine, traditionally used as a marker of bone resorption, allows us to judge the destruction of type I collagen, the filaments of which are connected by pyridine ligaments: pyridinoline and deoxypyridinoline. The latter is excreted into the bloodstream and excreted unchanged in the urine, and its levels are not affected by food intake. Pyrinx D content is assessed in the morning urine portion [45, 46].

Catabolism of the intercellular substance of connective tissue can be judged by the amount of excretion of *glycosaminoglycans* (GAG) in daily urine. In patients with various clinical variants of connective tissue diseases, there is usually an increased excretion of GAG in the urine [2, 9].

To assess collagen metabolism, serum *fibronectin* levels can also be determined. Fibronectin is a high-molecular-weight glycoprotein that binds collagen fibers, GAG, fibrin, etc. [45, 46]. Fibronectin deficiency usually indicates impaired collagen synthesis, which is also observed in DST.



To detect *magnesium* deficiency, its level in peripheral blood, as well as in serum and blood plasma, is determined. The determination of magnesium content in blood plasma is currently considered to be more physiological compared to the determination of magnesium levels in serum, as it interacts with plasma proteins. Based on the results of numerous studies, optimal levels of magnesium in blood plasma have been determined, which range from 0.80 to 0.85 mmol/L [10, 47]. Comparing plasma magnesium levels to serum magnesium levels is a diagnostic error. An actively developing area of modern clinical research is the establishment of reference values for magnesium levels in various blood biosubstrates [10, 45].

Magnesium can also be detected in daily urine. However, it should be noted that the content of magnesium in daily urine as a biomarker of its deficiency is characterized by a fairly wide variability [10]. In this regard, today the determination of the level of magnesium in the urine is mainly used to assess the saturation of the body's magnesium depot when taking magnesium-containing drugs and drugs that affect magnesium metabolism [10].

For early diagnosis of magnesium deficiency, its content in saliva is determined, which is normally 0.4–0.9 mmol/L. However, studies have found a correlation between the electrolyte composition of the consumed water and the content of magnesium ions in saliva, which affects the informative value of the results obtained [10, 48, 49].

In the literature, there is evidence of a statistically significant relationship between the concentration of matrix metalloproteinases (MMPs) in peripheral blood (MMP-1, MMP-9), magnesium levels, and the severity of varicose veins of the lower extremities. That is, according to the authors, the determination of the level of MMP and magnesium ions that characterize DST makes it possible to predict the development of chronic venous insufficiency of the lower extremities and assess its severity [50].

Prevention and treatment of DST

The management of patients with various manifestations of connective tissue dysplasia is currently being discussed by many specialists. The issues of supervision of patients with scoliosis, myopia, mitral valve prolapse, flat feet, and Marfan syndrome have been developed [2, 9]. However, there is still no unified program for the management of patients with multiple manifestations of DST.

There are treatment regimens and follow-up for patients with hereditary connective tissue diseases. Mandatory components of this observation are diet therapy, therapeutic exercises, massage, physiotherapy, psychotherapy, intake of vitamins, trace elements and metabolites [2, 3, 9]. The main purpose of these therapeutic measures is to stimulate collagen formation and correct disorders in the synthesis and catabolism of GAG.

The principles of diet therapy include the consumption of foods rich in protein, amino acids, individually selected dietary supplements containing essential amino acids, especially lysine, arginine, methionine, leucine, isoleucine and valine. In addition, foods enriched with macro- (calcium, phosphorus, magnesium) and microelements (copper, zinc, selenium, manganese, fluorine, vanadium, silicon, boron) are prescribed, which are cofactors of enzymes that activate collagen synthesis and are necessary for normal mineralization of the skeletal system [1–3, 9].

To normalize collagen synthesis, B vitamins are needed: B1, B2, B3, B6, which also normalize protein metabolism. Vitamins C and E, in addition to their positive effect on



collagen synthesis, have antioxidant activity. Zinc is a component of the body's 200 metalloenzymes, it is necessary for the synthesis of RNA, DNA, insulin, growth hormone, testosterone, the metabolism of proteins and lipids, as well as for the regulation of the function of T-lymphocytes. Selenium increases the protective properties of the immune system and has antioxidant activity [2, 3].

A regimen of drugs aimed at normalizing collagen metabolism should activate plastic processes in connective tissue and stimulate its biosynthesis. To stabilize the synthesis of collagen and other components of connective tissue, to stimulate metabolic and correct bioenergetic processes, according to the majority of specialists dealing with this problem, at least 3 courses of basic therapy should be prescribed with breaks during the year [2, 3, 9]. According to the results of biochemical analyses (determination of oxyproline, C-terminal telopeptides, pyrinx D), based on which it is possible to judge the degree of breakdown of collagen structures, it was found that longer rehabilitation therapy (3 courses within a year) brought a more stable result compared to 1 or 2 courses of therapy.

Conclusion. Patients with connective tissue pathology are at high risk of developing complications of pregnancy and childbirth, such as abortion, preeclampsia, placental insufficiency, labor abnormalities, etc., which requires special approaches to their management. Unfortunately, to date, most of the biochemical and genetic methods used in the diagnosis of DST are not available to practitioners. In addition, there are no uniform principles of clinical and instrumental examination of the patient and unified diagnostic criteria. Improvement of methods for diagnosing connective tissue pathology, and implementation of adequate preventive and therapeutic measures will prevent the development of complications and increase the likelihood of favorable pregnancy outcomes [9, 21, 26].

References:

1. Ilyina I.Yu., Dobrokhotova Yu.E., Zhdanova M.S. Influence of dysplasia of connective tissue on the development of genital prolapse. Russian Bulletin of Obstetrician-Gynecologist. 2009; 9(4):15–18.
2. Nechaeva G.I., Viktorova I.A. Dysplasia of connective tissue: terminology, diagnosis, tactics of patient management. Omsk: BLANKOM; 2007.
3. National recommendations of the Russian Scientific Medical Society of Therapists for the diagnosis, treatment and rehabilitation of patients with connective tissue dysplasia. Medical Bulletin of the North Caucasus. 2016; 11(1):2–76. DOI: 10.14300/mnnc.2016.11001.
4. Smolnova T.Yu., Adamyan L.V. Dynamics of phenotypic signs of connective tissue dysplasia syndrome in different age periods. Relevance of the problem in obstetrics and gynecology. Obstetrics and Gynecology. 2013; 4:74–79.
5. Ilyina I.Yu., Dobrokhotova Yu.E., Zhdanova M.S. Optimisation of treatment methods aimed at improving collagen formation processes in women with connective tissue dysplasia. Vestnik RUDN University. Medicine. 2009; 5:76–82. I.
6. Gazit Y., Jacob G., Grahame R. Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder. Rambam Maimonides Med J. 2016; 7(4).e0034. DOI: 10.5041/RMMJ.10261.



7. Kiss J., Balla B., Kosa J.P. et al. Gene expression patterns in the bone tissue of women with fibrous dysplasia. *Am J Med Genet A*. 2010; 152A (9):2211–2020. DOI: 10.1002/ajmg.a.33559.
8. Zoloto E.V. Dysplasia connective tissue — a problem in modern medicine. *University Hospital*. 2018; 4(29):109–116.
9. Nechaeva G.I., Yakovlev V.M., Konev V.P., et al. Dysplasia connective tissue: basic clinical syndromes, formulation of diagnosis, treatment. *Attending physician*. 2008; 2:22–28.
10. Torshin I.Yu., Gromova O.A. Dysplasia of connective tissue, cellular biology and molecular mechanisms of magnesium impact. *RMJ*. 2008; 16(4):230.
11. Boudin E., van Hul W. Sclerosing bone dysplasias. *Best Pract Res Clin Endocrinol Metab*. 2018; 32(5):707–723. DOI: 10.1016/j.beem.2018.06.003.
12. Martins K.F., Jarmy-DiBella Z.I., Fonseca A.M. et al. Evaluation of demographic, clinical characteristics and genetic polymorphism as risk factors for pelvic organ prolapse in Brazilian women. *Neurourol Urodynam*. 2011; 30:1325–1328.
13. Perumal R.K., Perumal S., Thangam R. et al. Ollagen-fucoidan blend film with the potential to induce fibroblast proliferation for regenerative applications. *Int J Biol Macromol*. 2018; 106:1032–1040.
14. Druk I.V., Rozhdestvenskiy A.S., Smyalovsky D.V., et al. Cerebral vascular syndrome dysplasia of connective tissue as a cause of subarachnoid hemorrhages in patients of young age. *S.S. Korsakov Journal of Neurology and Psychiatry*. 2018; 118(12-2):15–22. DOI: 10.17116/jnevro201811812215.
15. Forlino A., Marini J.C. Osteogenesis imperfecta. *Lancet*. 2016; 387(10028):1657–1671. DOI: 10.1016/S0140-6736 (15) 00728-X.
16. Marini J.C., Forlino A., Bächinger H.P. et al. Osteogenesis imperfecta. *Nat Rev Dis Primers*. 2017; 18(3):17052. DOI: 10.1038/nrdp.2017.52.
17. Meester J.N., Verstraeten A., Schepers D. et al. Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome. *Ann Cardiothorac Surg*. 2017; 6(6):582–594. DOI: 10.21037/acs.2017.11.03.
18. Veropotvelyan P.N., Tsekhmistrenko I.S., Veropotvelyan N.P., Gatselyuk S.V. Strategicheskiy vzglyad na faktory riska prolapsa genitalia i sposoby ikh korrektsii [Strategic view on risk factors of genital prolapse and methods of their correction]. *Medical aspects of women's health*. 2016; 3(100):66–74.
19. Shcherbinina N.A., Alaya Lamia. Risk factors for genital prolapse in perimenopausal women with connective tissue dysplasia and their correction. *Bulletin of Problems of Biology and Medicine*. 2016; 2(128):135–139.
20. Garcia-González M., Rodríguez-Lozano B., Bustabad S., Ferraz-Amaro I. Undifferentiated connective tissue disease: predictors of evolution into definite disease. *Clin Exp Rheumatol*. 2017; 35(5):739–745.
21. Khodzhaeva Z.S., Gurbanova S.R. Clinical and pathogenetic justification of the use of magnesium preparations in pregnant women with isthmio-cervical insufficiency and undifferentiated dysplasia of connective tissue. *Obstetrics and Gynecology*. 2011; 3:57–63.
22. Shilov A.M., Melnik M.V., Sviridova A.Y. Dysplasia of connective tissue and magnesium deficiency. *Pharmateca*. 2010; 20:35–38.



23. Barbagallo M., Belvedere M., Dominguez L.J. Magnesium homeostasis and aging. *Magnesium Research*. 2009; 22(4):235–246.
24. Shankar H., Kumar N., Sandhir R. et al. Association of dietary intake below recommendations and micronutrient deficiencies during pregnancy and low birthweight. *J Perinat Med*. 2019; 47(7):724–731. DOI: 10.1515/jpm-2019-0053.
25. Wallace E., Lowry J., Smith S.M., Fahey T. The epidemiology of malpractice claims in primary care: a systematic review. *BMJ Open*. 2013; 3(7): e002929. DOI: 10.1136/bmjopen-2013-002929.
26. Chaika V.K., Zheleznaya A.A., Luneva N.N. Management of complicated pregnancy in pregnant women with undifferentiated dysplasia of connective tissue (clinical case). *Medical and social problems of the family*. 2019; 24(1):104–111.
27. Eltayeb R., Rayis D.A., Sharif M.E. et al. The prevalence of serum magnesium and iron deficiency anaemia among Sudanese women in early pregnancy: a cross-sectional study. *Trans R Soc Trop Med Hyg*. 2019; 113(1):31–35. DOI: 10.1093/trstmh/try109.
28. Gracheva O.N., Gromova O.A. *Dysplasia of connective tissue during pregnancy: phenomenology, etiology, magnesium deficiency and molecular mechanisms*. Moscow: Miklos; 2012.29
29. Zhabchenko I.A., Oleshko V.F. Features of the course of pregnancy and childbirth, the state of the fetus and newborn in women with disorders of the obturation function of the cervix during gestation. *Protection of motherhood and childhood*. 2016; 1(27):5–9.
30. Zheleznaya A.A., Vustenko V.V., Mezhoval O.K. Znachenie undifferentiated dysplasia connective tissue in obstetrics and gynecology practice. *Medical and social problems of the family*. 2015; 20(3–4):55–57.
31. Anastasyeva V.G., Trunchenko N.V. Osobennosti techeniya pregnancii i otkhoda rodov u pregnannykh s prolapsom mitral'nogo valvea [Features of the course of pregnancy and the outcome of childbirth in pregnant women with mitral valve prolapse]. *Bulletin of the East-Siberian Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences*. 2007; 3(55):18–22.
32. Manuck T.A. The genomics of prematurity in an era of more precise clinical phenotyping: a review. *Semin Fetal Neonatal Med*. 2016; 21(2):89–93. DOI: 10.1016/j.siny.2016.01.001.
33. Vink J., Feltovich H. Cervical etiology of spontaneous preterm birth. *Semin Fetal Neonatal Med*. 2016; 21(2):106–112. DOI: 10.1016/j.siny.2015.12.009.
34. Komissarova L.M., Karachaeva A.N., Kesova M.I. Course of pregnancy and childbirth in dysplasia of connective tissue. *Obstetrics and Gynecology*. 2012; 3:4–8.
35. Kan N.E., Tyutyunnik V.L., Amiraslanov E.Yu., et al. Obstetric complications and undifferentiated dysplasia of connective tissue. *Clinical and Experimental Surgery. Journal named after Acad. B.V. Petrovsky*. 2015; 2:47–52.
36. Kerimkulova N.V., Nikiforova N.V., Torshin I.Yu., et al. Pregnancy and childbirth in women with dysplasia of connective tissue and iron deficiency anemia. *Issues of Gynecology, Obstetrics and Perinatology*. 2014; 13(5):11–21.
37. Kononenko I.S., Zhukova N.P. Genetic predictors of isthmic-cervical insufficiency. *Russian Bulletin of Obstetrician-Gynecologist*. 2020; 20(2):29–34. DOI: 10.17116/rosakush20202002129.



38. Kravchenko E.N., Tyshkevich O.S. Diagnostika undifferentiated forms dysplasia connective tissue [Diagnostics of undifferentiated forms of dysplasia of connective tissue]. Vesti MANEB in the Omsk region. 2014; 1(4):4–7.
39. Kerchelaeva S.B., Kuznetsova O.V., Burdenko M.V., et al. Pathology of the Heart and Pregnancy: Textbook. Moscow; 2018:9–43.
40. Kudinova E.G. Correction of changes in the system of hemostasis in pregnant women with hereditary disorders of connective tissue with the use of vitamin-mineral complexes. RMJ. Mother and Child. 2014; 22(19):1406–1411.
41. Vagelli R., Tani C., Mosca M. Pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Practical messages from the EULAR guidelines. Pol Arch Intern Med. 2017; 127(2):115–121. DOI: 10.20452/pamw.3906.
42. Watson S.P., Lowe G.C., Lordkipanidzé M., Morgan N.V. GAPP consortium. Genotyping and phenotyping of platelet function disorders. J. Thromb Haemost. 2013; 11(Suppl. 1):351–363. DOI: 10.1111/jth.12199.
43. Stevens D.U., Al-Nasiry S., Bulten J., Spaanderman M.E.A. Decidual vasculopathy in preeclampsia: lesion characteristics relate to disease severity and perinatal outcome. Placenta. 2013; 34(9):805–809. DOI: 10.1016/j.placenta.2013.05.008.
44. Smetnik V.P. Meditsina klimakteriya [Medicine of climactery]. Moscow: Litera; 2006.45 . Tarabanova O.V., Krutova V.A., Ordokova A.A., et al. Laboratory and immunohistochemical predictors of genital prolapse recurrence. Sechenov Bulletin. 2017; 4(30):42–50.
45. Fadeeva T.S. Biokhimicheskie i klinicheskie proyavleniya dysplasia connective tissue u zhenshchina s opolozheniyami i vydropaniyami vnutrennykh polovykh organov [Biochemical and clinical manifestations of dysplasia of connective tissue in women with omissions and drops of internal sexual organs]. Education and Science in Modern Conditions. 2016; 2–1 (7):61–62.
46. Joosten M.M., Gansevoort R.T., Mukamal K.J. et al. PREVEND Study Group. Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study. Hypertension. 2013; 61(6):1161–1167. DOI: 10.1161/HYPERTENSIONAHA.113.01333.
47. Karakov K.G., Elbekyan K.S., Markarova G.V. Osnovy biokhimii tissues i organov polnosti orta: uchebnoe posobie [Fundamentals of biochemistry of tissues and organs of oral cavity: textbook]. Stavropol; 2012.
48. Henkin R.I., Gouliouk V., Fordyce A. Distinguishing patients with glossopyrosis from those with oropyrosis based upon clinical differences and differences in saliva and erythrocyte magnesium. Arch. Oral Biol. 2012; 57(2):205–210. DOI: 10.1016/j.archoralbio.2011.08.010.
49. Kalinin R.E., Suchkov I.A., Pshennikov A.S., et al. Concentration of matrix metalloproteinases and magnesium ions in varicose veins of lower limbs. Angiology and Vascular Surgery. 2016; 22(4):24–28